The merger integrates EVERSANA’s commercialization services with Waltz Health’s AI-powered payer tools to address patient affordability, streamline drug access, and reduce costs for high-expense therapies such as GLP-1s.
A JAMA Network Open study reveals that patients with private insurance can face monthly costs nearing $600 after a cancer diagnosis, highlighting the disparities based on cancer stage and calling for stronger financial support policies.